Pfizer Inc
NYSE: PFE
$25.77
-$0.40 (-1.5%)
Closing Price on November 26, 2024
PFE Articles
24/7 Wall St. screened the Merrill Lynch Income Portfolio portfolio looking for high-yielding Buy-rated companies and found the following five from different sectors that are solid plays now.
Published:
Last Updated:
The April 30 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Published:
Last Updated:
As of the most recently reported period, short sellers favored Apple, Intel and Pfizer above all other Dow stocks.
Published:
Last Updated:
It's an impressive day when two IPOs are well received when drug-selling revenues are unlikely for quite some time, and even longer before profits can be considered.
Published:
Last Updated:
Drugmaker Pfizer beat estimates on both the top and bottom lines for the first quarter, and shares rallied after the report.
Published:
Last Updated:
24/7 Wall St. has put together a preview of Apple, Pfizer and other Dow companies scheduled to report their quarterly results this week.
Published:
Last Updated:
The April 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Published:
Last Updated:
As of the most recently reported period, short sellers favored Pfizer, Apple and Intel above all other Dow stocks.
Published:
Last Updated:
Here is a slate of 15 companies that most retirees likely would want to own in their portfolio now, including AT&T, Boeing, Pfizer and Walmart.
Published:
Last Updated:
The March 29 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased, with two major movers in the group.
Published:
Last Updated:
As of the most recently reported period, short sellers favored Pfizer, Apple and Intel above all other Dow stocks.
Published:
Last Updated:
Sangamo Therapeutics shares jumped on Tuesday after the company announced interim data from its midstage hemophilia trial in collaboration with Pfizer.
Published:
Last Updated:
According to Credit Suisse, Pfizer investors might be getting to make up some of that relative underperformance of late.
Published:
Last Updated:
The March 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased, with two major movers in the group.
Published:
Last Updated:
As of the most recently reported period, short sellers favored Pfizer, Apple and Intel above all other Dow stocks. Many others saw sizable increases in their short interest.
Published:
Last Updated: